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BACKGROUND
• Cancer and cardiovascular disease are the two most prevalent diseases around the world.1
• Coronary artery disease is frequently encountered in cancer patients. It may predate the development of 
cancer or result from treatment of cancer itself.2
• The treatment options available for this population are based on those studied in general population.3
• Few studies have been focused on the relationship between malignancy and acute coronary syndromes (ACS).
We aimed to evaluate the incidence of malignancy in an acute coronary syndrome population and 
its impact on outcome.
Purpose
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METHODS
1486 patients  admitted 
with ACS from
Jan 2012 – December 2014
Group 1:
pts with active cancer (<5years)
(n=58, 3.9%)
Group 2:
pts without cancer 
(n=1428, 96.1%)
• For each group we compared clinical features and adverse events. 
• Primary endpoint was the occurrence of death at 1 year; follow-up was completed in 98% of patients.
Excluded: 
4 pts with Type 2 MI
 28% cancer diagnosis < 1 year
 90% had solid tumors
 10.3% had metastasis
 24.1% were treated with 
chemotherapy
 22.9 % were treated with  
radiotherapy
RESULTS
Variables Group 1 Group 2 P
Age (years) 69 ± 11 63 ± 13 0.001
Women (%) 20.7 21.7 0.8
Cardiovascular Risk Factors
Hypertension (%) 65.5 62.9 0.78
Diabetes (%) 
Dyslipidaemia (%) 46.6 57.6 0.105
Smoking (%) 22.4 31.9 0.15
Previous smoker (%) 36.2 20.0 0.05
Previous Vascular Disease
Myocardial Infarction (%) 20.7 14.5 0.18
Angina (%) 19.0 15.5 0.46
PTCA (%) 8.6 10.0 1.0
CABG (%) 6.9 4.4 0.33
Stroke (%) 15.5 7.4 0.038
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Killip class > 1 (%) 19 12.9 0.17





Variables Group 1 Group 2 P
Revascularization (%) 79.3 86.8 NS
PTCA in 2nd time (%) 1.8 10.3 NS
CABG (%) 19 12.9 0.037
Medical Treatment
Aspirin (%) 100 99.3 NS
Clopidogrel (%) 94.8 98.9 0.035
Beta blockers (%) 86.2 89.1 NS
ACE inhibitors  (%) 94.8 92.4 NS
Statins  (%) 100 98.4 NS
Diuretics  (%) 27.6 19.2 0.008





not revascularized BMS DES POBA CABG
• In hospital medical treatment and procedures • Revascularization options in cancer population
RESULTS
Variables Group 1 Group 2 P
Blood transfusion (%) 4.0 1.6 0.207
Acute heart failure  (%) 41.4 26.5 0.016
Reinfarction (%) 1.7 2.2 0.78
Post-infarction angina  (%) 12.1 5.1 0.016
New onset atrial fibrillation (%) 6.9 2.8 <0.001
In-hospital mortality (%) 3.4 2.4 0.65
























Age > 60 years old 1.03 1.00 1,06 0.047
eGRF < 60 ml/min 2.98 1.52 5.86 <0.001
Left ventricle function > 50% 0.28 0.13 0.59 0.001
Acute heart failure 3.72 2.05 6.77 <0.001
Active cancer 2.45 1.33 4.49 0.004
CONCLUSION
• In our population the incidence of cancer was 3.9%. This population were older and had more comorbidities.
• The medical treatment used in cancer population was, in general, the same used in cohort without cancer, but a high percentage of 
patients received a more conservative approach.
• Patients with cancer had long term worse prognosis. After adjusting for confounders, the presence of malignancy  reveals as one of the 
independent predictors of mortality. 
• Cox Regression - independent predictors of all causes long term mortality
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